Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan
Phase 2
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 480
- Registration Number
- NCT01263470
Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 179
- Registration Number
- NCT01263509
Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 230
- Registration Number
- NCT01263483
Efficacy and Safety Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder
- First Posted Date
- 2010-12-07
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 600
- Registration Number
- NCT01255787
Efficacy of Tinoridine in Treating Pain and Inflammation in Adults
- First Posted Date
- 2010-10-20
- Last Posted Date
- 2012-01-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 342
- Registration Number
- NCT01224756
Effect of Dexlansoprazole on Bone Homeostasis
Phase 1
Completed
- Conditions
- HomeostasisBone and Bones
- Interventions
- First Posted Date
- 2010-10-07
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 115
- Registration Number
- NCT01216293
TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery
Phase 3
Completed
- Conditions
- Hemorrhage
- Interventions
- Device: Surgicel® OriginalBiological: TachoSil®
- First Posted Date
- 2010-08-31
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Takeda
- Target Recruit Count
- 253
- Registration Number
- NCT01192022
Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
- First Posted Date
- 2010-08-11
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 469
- Registration Number
- NCT01179516
Bivalent Norovirus Vaccine Study
Phase 1
Completed
- Conditions
- Gastroenteritis
- Interventions
- Biological: SalineBiological: NoV GI.1/GII.4 Bivalent VLP Vaccine
- First Posted Date
- 2010-07-23
- Last Posted Date
- 2018-11-23
- Lead Sponsor
- Takeda
- Target Recruit Count
- 102
- Registration Number
- NCT01168401
- Locations
- 🇺🇸
Saint Louis University, Saint Louis, Missouri, United States
🇺🇸Navy Medical Research Center, Silver Springs, Maryland, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
- First Posted Date
- 2010-07-15
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 462
- Registration Number
- NCT01163266
© Copyright 2025. All Rights Reserved by MedPath